利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

145 条记录 (耗时 0.047 秒)

    HIV replication inhibiting pyrimidines
    42.
    发明授权
    HIV replication inhibiting pyrimidines 有权
    HIV复制抑制嘧啶

    公开(公告)号：US06878717B2

    公开(公告)日：2005-04-12

    申请号：US09430966

    申请日：1999-11-01

    申请人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    发明人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    IPC分类号： C07D239/47 ,  A61K20060101 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/675 ,  A61K31/715 ,  A61P31/18 ,  C07D20060101 ,  C07D239/42 ,  C07D239/46 ,  C07D239/48 ,  C07D239/50 ,  C07D239/80 ,  C07D401/12 ,  C07D403/12

    CPC分类号： A61K31/505 ,  A61K31/5513

    摘要： This invention concerns the use of compounds of formula: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=-a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

    摘要翻译： 本发明涉及下式化合物的用途：N-氧化物，药学上可接受的加成盐，季胺及其立体化学异构形式，其中-a 1 = -a 2 -a 3 = a < 与所连接的乙烯基形成苯基，吡啶基，嘧啶基，哒嗪基或吡嗪基; n为0〜4; 并在可能的情况下5; R 1是氢，芳基，甲酰基，C 1-6烷基羰基，C 1-6烷基，C 1-6烷氧基羰基，取代的C 1-6烷基或取代的C 1-6烷氧基C 1-6烷基羰基; 每个R 2独立地是羟基，卤素，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 3-7环烷基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（ C 1-6烷基）氨基，多卤代甲基，多卤甲氧基，多卤代甲硫基，-S（= O）p R 6，-NH-S（= O）p R 6，-C（= O）R 6， NHC（= O）H，-C（= O）NHNH 2，-NHC（= O）R 6，-C（= NH）R 6或5元杂环; p为1或2; L是任选取代的C 1-10烷基，C 2-10烯基，C 2-10炔基或C 3-7环烷基; 或L是-X-R 3，其中R 3是任选取代的苯基，吡啶基，嘧啶基，吡嗪基或哒嗪基; X是-NR 1 - ， - NH-NH-，-N = N-，-O-，-C（= O） - ， - CHOH-，-S-，-S（= O） - 或 - S（= O）2-; Q是氢，C 1-6烷基，卤素，多卤代-C 1-6烷基或任选取代的氨基; Y表示羟基，卤素，C 3-7环烷基，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（C 1-6烷基）氨基 ，多卤甲基，多卤甲氧基，多卤甲硫基，-S（= O）pR 6，-NH-S（= O）pR 6，-C（= O）R 6，-NHC（= O） -C（= O）NHNH

    2,4-disubstituted triazine derivatives
    43.
    发明授权
    2,4-disubstituted triazine derivatives 失效
    2,4-二取代的三嗪衍生物

    公开(公告)号：US06638932B1

    公开(公告)日：2003-10-28

    申请号：US09831808

    申请日：2001-08-02

    申请人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    发明人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    IPC分类号： C07D25116

    CPC分类号： A61K9/146 ,  Y10S977/775 ,  Y10S977/915

    摘要： This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein —a1═a2—a3═a4— forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl or substituted C1-6alkyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR4, —NH—S(═O)pR4, —C(═O)R4, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R4, —C(═NH)R4 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

    摘要翻译： 本发明涉及配制N-氧化物的化合物，药学上可接受的加成盐，季胺及其立体化学异构形式的用途，其中-a 1 = a 2 -a 3 = a 4 - 与连接的乙烯基形成苯基，吡啶基，嘧啶基，哒嗪基或吡嗪基; n为0〜4; 并在可能的情况下5; R 1是氢，芳基，甲酰基，C 1-6烷基羰基，C 1-6烷基，C 1-6烷氧基羰基或取代的C 1-6烷基; 每个R 2独立地是羟基，卤素，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 3-7环烷基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（ C 1-6烷基）氨基，多卤代甲基，多卤甲氧基，多卤甲硫基，-S（= O）p R 4，-NH-S（= O）p R 4，-C（= O）R 4， = O）H，-C（= O）NHNH 2，-NHC（= O）R 4，-C（= NH）R 4或5元杂环; p为1或2; L是任选取代的C 1-10烷基，C 2-10烯基，C 2-10炔基或C 3-7环烷基; 或L是-X-R 3，其中R 3是任选取代的苯基，吡啶基，嘧啶基，吡嗪基或哒嗪基; X是-NR 1 - ， - NH-NH-，-N = N-，-O-，-C（= O） - ， - CHOH-，-S-，-S（= O） - 或 - S（= O）2-; 芳基是任选取代的苯基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。

    HIV inhibiting pyrimidine derivative
    44.
    发明授权
    HIV inhibiting pyrimidine derivative 有权
    HIV抑制嘧啶衍生物

    公开(公告)号：US06197779B1

    公开(公告)日：2001-03-06

    申请号：US09276360

    申请日：1999-03-25

    申请人： Koenraad Jozef Lodewijk Marcel Andries ,  Bart De Corte ,  Marc René De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Marcel August Constant Janssen ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    发明人： Koenraad Jozef Lodewijk Marcel Andries ,  Bart De Corte ,  Marc René De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Marcel August Constant Janssen ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

    IPC分类号： A61K31506

    CPC分类号： C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/49 ,  C07D239/50 ,  C07D401/12

    摘要： This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0 to 4; Q is hydrogen or —NR1R2; R1 and R2 are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each C1-12alkyl may optionally be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl,; and R4 is hydroxy, halo, optionally substituted C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R5 is hydrogen or C1-4alkyl; L is optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl; or L is —X1—R6 or —X2-Alk-R7 wherein R6 and R7 are optionally substituted phenyl; X1 and X2 are —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; Alk is C1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.

    摘要翻译： 本发明涉及N-氧化物，其药学上可接受的加成盐和立体化学异构形式的化合物的用途，其中A是CH，CR 4或N; n为0〜4; Q是氢或-NR1R2; R1和R2选自氢，羟基，C1-12烷基，C1-12烷氧基，C1-12烷基羰基，C1-12烷氧基羰基，芳基，氨基，一或二（C1-12烷基）氨基，单或二（C1-12烷基） 其中每个C 1-12烷基可以任选被取代; 或R 1和R 2可以一起形成吡咯烷基，哌啶基，吗啉基，叠氮基或单或二（C 1-12烷基）氨基C 1-4亚烷基; R 3是氢，芳基，C 1-6烷基羰基，任选取代的C 1-6烷基，C 1-6烷氧基羰基。 R4为羟基，卤素，任选取代的C 1-6烷基，C 1-6烷氧基，氰基，氨基羰基，硝基，氨基，三卤代甲基，三卤代甲氧基; R5是氢或C1-4烷基; L是任选取代的C 1-10烷基，C 3-10烯基，C 3-10炔基，C 3-7环烷基; 或L是-X1-R6或-X2-Alk-R7，其中R6和R7是任选取代的苯基; X1和X2是-NR3-，-NH-NH-，-N = N-，-O - ， - S - ， - S（= O） - 或-S（= O） Alk是C1-4烷二基; 芳基是取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。 它还涉及作为式（I）化合物的亚组的新化合物，其制备方法和包含它们的组合物。

    Hiv Inhibiting Bicyclic Pyrimdine Derivatives
    46.
    发明申请
    Hiv Inhibiting Bicyclic Pyrimdine Derivatives 有权

    公开(公告)号：US20080085907A1

    公开(公告)日：2008-04-10

    申请号：US11718181

    申请日：2005-10-27

    申请人： Jerome Guillemont ,  Mikael Paugam ,  Bruno Delest ,  Jan Heeres ,  Paulus Lewi ,  Paul Adriaan Janssen ,  Frank Javier Arts

    发明人： Jerome Guillemont ,  Mikael Paugam ,  Bruno Delest ,  Jan Heeres ,  Paulus Lewi ,  Paul Adriaan Janssen ,  Frank Javier Arts

    IPC分类号： C07D473/36 ,  A61K31/519 ,  A61K31/52 ,  A61P31/18 ,  C07D487/04 ,  C07D239/70 ,  C07D473/32

    CPC分类号： C07D487/04 ,  C07D473/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/34

    摘要： HIV replication inhibitors of formula (1) N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0, 1, 2, 3 and in certain cases also 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl: optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; substituted amino; polyhalomethyl; polyhalomethylthio; —S(═O)pR6; C(═NH)R6; R2a is CN; amino; substituted amino; optionally substituted C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R16; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4 alkyl; R7 or —X—R4; R3 is CN; amino; C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R16: substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4 alkyl; R7; —X—R7; R4 is halo; OH; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; CN; nitro; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C1-4alkyl)amino or R7; -A-B— is —CR5═N—, —N═N—, —CH2—CH2—, —CS—NH—, —CO—NH—, —CH═CH—; pharmaceutical compositions comprising these; methods for the preparation of these compounds and compositions; the use of these compounds for the prevention or the treatment of HIV infection.